Abstract B137: Targeting MICAL2 sensitizes pancreatic cancer cells to gemcitabine and enhances therapeutic response
Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal malignancy, largely due to rapid development of resistance to standard chemotherapies such as gemcitabine. MICAL2 is a redox-dependent regulator of actin dynamics that is overexpressed in PDAC, but its role in therapeutic resistance remains poorly un...